GlassScriptPhysician profile
Moises Lutwak
NPI 1821735325
$8,258.78
in general payments reported to CMS, 2019-2025
26 companies · $2,951 in 2025
The $2,951 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,016 · 2023: $854 · 2024: $3,439 · 2025: $2,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,954 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,954.29 |
| Education | $288.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,164.57 | 2022-2025 | |
| Janssen Biotech, INC. | $1,139.86 | 2024-2025 | Tremfya |
| Genzyme Corporation | $557.56 | 2024-2025 | |
| Amgen INC. | $530.65 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $529.34 | 2022-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $524.90 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $476.96 | 2022-2024 | Sotyktu |
| Ucb, INC. | $426.86 | 2023-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $354.66 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $199.19 | 2023-2025 | Dupixent |
| Botanix Sb INC | $192.69 | 2025 | Sofdra |
| Incyte Corporation | $162.52 | 2023-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $141.68 | 2024 | Tremfya |
| Verrica Pharmaceuticals INC. | $121.01 | 2024 | Ycanth |
| Convatec INC. | $118.70 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.89 | 2024-2025 | Spevigo |
| Dermavant Sciences, INC. | $103.53 | 2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $82.11 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Lilly USA, LLC | $67.06 | 2024 | Taltz, Ebglyss |
| Pfizer INC. | $56.49 | 2025 | |
| Kyowa Kirin, INC. | $27.76 | 2024 | Poteligeo |
| Mayne Pharma Commercial LLC | $25.72 | 2025 | |
| Blueprint Medicines Corporation | $24.07 | 2025 | Ayvakit |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.34 | 2024 | Jublia, Arazlo |
| Lnhc, INC | $16.67 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moises Lutwak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.